Tobias Sinnberg

27PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Apr 09, 2026
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.

Elena Sophia Lindner, Jakob Admard, German Demidov

|Oct 16, 2025
Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma.

Corinna Kosnopfel, Tobias Sinnberg, Shrunal Mane

|Jun 25, 2025
Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance.

Antonia Kolb, Ana-Marija Kulis-Mandic, Matthias Klein

|Nov 09, 2024
Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target.

Matti Böcker, Eftychia Chatziioannou, Heike Niessner

|May 11, 2024
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils.

Simone Wendlinger, Jonas Wohlfarth, Claudia Siedel

|Mar 28, 2024
Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors.

Zhe Peng, Bernhard Gillissen, Antje Richter

Pageof 5

Frequent Collaborators

13 joint publications

Heike Niessner

4 joint publications

Corinna Kosnopfel

3 joint publications

German Demidov

3 joint publications

Andrea Forschner